Cognitive Remediation for Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring cognition, schizophrenia, treatment
Eligibility Criteria
Inclusion Criteria: Current DSM-IV diagnoses of schizophrenia or schizoaffective disorder Stable clinical course and antipsychotic treatment on a new generation antipsychotic other than clozapine and/or a dose of first generation antipsychotic equivalent to 10 mg. or less of haloperidol for one month prior to enrollment Age between 18 and 64 years Voluntary consent after receiving full information about the study Exclusion Criteria: Documented history of neurological disorder or significant head trauma with extended loss of consciousness Physical limitations (e.g., with hearing or vision) that would interfere substantially with the use of computer-based exercises Current treatment with a first generation antipsychotic medication at a dose equivalent to more than 10 mg. of haloperidol Current treatment with benztropine mesylate at a daily does greater than 4 mg Current treatment with trihexyphenidyl at a daily dose greater than 15 mg Current treatment that combines benztropine mesylate with trihexyphenidyl Current treatment with diphenhydramine Current competitive employment or participation (current or within past 3 months) in a program designed to secure competitive employment (e.g., CWT) Mini Mental Status Examination (MMSE) score of less than 23 Diagnosis of current Substance Dependence according to DSM-IV criteria
Sites / Locations
- VA Maryland Health Care System, Baltimore
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2
computer-assisted cognitive remediation (CACR)
computer-based cognitive activity